William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The controlling shareholder in Novo Nordisk put in a request for EU approval for the deal on Oct. 31. The EU antitrust ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk’sNOVO.B-1.06%decrease ... in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients who also suffered ...

Novo Nordisk is urging the U.S. Food and Drug Administration (FDA) to block ‘copycat’ versions of its popular weight-loss and diabetes drugs, arguing that the complexities of manufacturing ...

Earlier, Novo Nordisk A/S (NYSE:NVO ... Also Read: Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug However, he noted that no definitive cause of death is identified ...

Many companies, including market leaders Novo Nordisk (DK:NOVO.B) (NVO) and Eli Lilly & Co. (LLY), are working to develop a weight-loss pill. Jefferies is confident Viking's stock still has plenty ...